Author:
Zheng Xiaohong,Wang Can,Chen Feng,Li Shenglan,Zhang Hua,Dong Gehong,Yang Shoubo,Kang Xun,Kang Zhuang,Han Chunlei,Yin Shuo,Li Wenbin
Reference44 articles.
1. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors;Jahnke;J. Neuro Oncol.,2006
2. Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice;Deckert;Acta Neuropathol.,2014
3. Emerging insights into origin and pathobiology of primary central nervous system lymphoma;You;Cancer Lett.,2021
4. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial;Kalakonda;Lancet. Haematol.,2020
5. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement;Bobillo;Haematologica,2018